Clinical Research Directory
Browse clinical research sites, groups, and studies.
Oral Mecobalamin for TKI-Associated Hand-Foot Syndrome in Advanced Thyroid Cancer
Sponsor: Li Zhihui
Summary
This study evaluates the efficacy and safety of oral mecobalamin for the treatment of tyrosine kinase inhibitor (TKI)-associated hand-foot syndrome (HFS) in patients with advanced thyroid cancer. 100 patients will be randomly assigned to receive either routine skin care with topical urea ointment alone (control group) or routine skin care plus oral mecobalamin (0.5 mg three times daily) for 8 weeks. The primary outcome is the proportion of patients with HFS grade improvement at week 8.
Official title: Oral Mecobalamin for the Treatment of Tyrosine Kinase Inhibitor-Associated Hand-Foot Syndrome in Patients With Advanced Thyroid Cancer: A Single-Center, Open-Label, Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-04-12
Completion Date
2026-03-12
Last Updated
2026-11-03
Healthy Volunteers
No
Conditions
Interventions
Mecobalamin
Oral mecobalamin 0.5 mg, 3 times daily, for 8 weeks.
Urea Ointment
Topical urea ointment applied to hands and feet 3 times daily, for 8 weeks.
Locations (1)
West China Hospital, Sichuan University
Chengdu, Sichuan, China